GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spruce Biosciences Inc (NAS:SPRB) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Spruce Biosciences (Spruce Biosciences) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of May. 17, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Spruce Biosciences EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Spruce Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Spruce Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Spruce Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spruce Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spruce Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Spruce Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.


Spruce Biosciences  (NAS:SPRB) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Spruce Biosciences EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Spruce Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Spruce Biosciences (Spruce Biosciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spruce Biosciences Inc (NAS:SPRB) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)
Comparable Companies
YS DYAI MTNB DTIL OKYO COYA AGLE GDTC IMUX BIOR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
611 Gateway Boulevard, Suite 740, South San Francisco, CA, USA, 94080
Website
https://www.sprucebiosciences.com
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
Executives
Percival Barretto-ko director 611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO CA 94080
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Niall O'donnell director C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
Charlton Ralph William Iii officer: Chief Medical Officer 2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94104
Javier B. Szwarcberg director, officer: Chief Executive Officer 2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94014
Kirk Ways director C/O 2001 JUNIPERO SERRA BOULEVARD, SUITE 540, DALY CITY CA 94014
Camilla V Simpson director 20 ELAINE AVE., MILL VALLEY CA 94941
Bali Muralidhar director C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077
Jonas Hansson director 18 AVENUE D'OUCHY, LAUSANNE V8 CH-1006
Rivervest Venture Fund Iii (ohio), L.p. 10 percent owner 11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502
Healthcap Viii, L.p. 10 percent owner 18 AVENUE D'OUCHY, C/O HEALTHCAP VIII GP SA, CH 1006 LAUSANNE V8 1006
Moghrabi Dina Chaya director 22 GLEDHOW GARDENS, FLAT 2, LONDON X0 SW5 0AZ
Omega Fund Vi Gp Manager, Ltd. 10 percent owner 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Samir M. Gharib officer: Chief Financial Officer 2655 PINE STREET, #6, SAN FRANCISCO CA 94115
Richard King director, officer: Chief Executive Officer C/O KOS PHARMACEUTICALS INC, 1001 BRICKELL AVE 25TH FL, MIAMI FL 33131